Information Provided By:
Fly News Breaks for September 27, 2016
LLY
Sep 27, 2016 | 07:14 EDT
Goldman analyst Jami Rubin upgraded Eli Lilly to Buy and increased its price target to $95 from $89 saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. Rubin projects $12.5B of new product sales by 2020 and double digit earnings growth over the next five years, even without Sola. The analyst sees a 35%, up from 25%, probability of success for Sola with a bull case scenario that can lead to almost $7.5B in peak sales and "super charge" earnings. Even without Sola, Rubin sees favorable risk/reward given durability of earnings and said it is the least exposed to above-CPI price increases.
News For LLY From the Last 2 Days
LLY
Mar 18, 2024 | 10:41 EDT
Oprah Winfrey is hosting a television special on Monday to discuss how WeightWatchers (WW) and weight loss drugs helped her with weight and obesity, CNN's Lisa Respers France reports. "An Oprah Special: Shame, Blame and the Weight Loss Revolution" will be a sit-down conversation around the "radical impact of prescription weight loss medications," according to promotional material for the special. Winfrey, who recently exited the board of WW, will moderate the conversation in front of a live audience with medical experts to explore "prevailing questions and concerns surrounding the impact on our health care, economy, lifestyle and culture," according to a press release for the event. "It is a very personal topic for me and for the hundreds of millions of people impacted around the globe who have for years struggled with weight and obesity," Winfrey said. Weight loss drug options include Eli Lilly's (LLY) Mounjaro and Novo Nordisk's (NVO) Ozempic. Reference Link